0001104659-23-065693.txt : 20230530 0001104659-23-065693.hdr.sgml : 20230530 20230530080013 ACCESSION NUMBER: 0001104659-23-065693 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20230530 FILED AS OF DATE: 20230530 DATE AS OF CHANGE: 20230530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKANDA CORP. CENTRAL INDEX KEY: 0001888014 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41324 FILM NUMBER: 23971459 BUSINESS ADDRESS: STREET 1: 1A, 1B LEAROYD ROAD CITY: NEW ROMNEY STATE: X0 ZIP: TN28 8XU BUSINESS PHONE: 442034889514 MAIL ADDRESS: STREET 1: 77 KING STREET WEST, SUITE 400 STREET 2: C/O DENTONS CANADA LLP CITY: TORONTO STATE: A6 ZIP: M5K 0A1 6-K 1 tm2317215d1_6k.htm FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2023

 

Commission File Number: 001-41324

 

 

 

AKANDA CORP.

(Registrant’s Name)

 

 

 

1a, 1b Learoyd Road

New Romney TN28 8XU, United Kingdom

(Address of Principal Executive Office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x            Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 

 

 

Attached hereto as Exhibit 99.1 and incorporated by reference herein is Akanda Corp.’s press release, dated May 29, 2023.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AKANDA CORP.
       
  By : /s/ Katie Field
  Name : Katie Field
  Title : Executive Director

 

Date: May 30, 2023

 

 

 

 

EXHIBIT INDEX

 

Exhibit No. Description
99.1 Press release, dated May 29, 2023.

 

 

EX-99.1 2 tm2317215d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

AKANDA CORP. ANNOUNCES TERMINATION OF LOAN AGREEMENT

  

FRANKFURT, Germany & LONDON --(BUSINESS WIRE)-- International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda and Veridia Canada Ltd. (the “Lender”) have mutually agreed to terminate the loan agreement between the parties previously announced on April 18, 2023 (the “Loan Agreement”). Akanda has returned all funds provided under under the terms of the Loan Agreement and has no further obligations owing to the Lender pursuant to the Loan Agreement.

 

About Akanda Corp.

 

Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda’s portfolio includes Holigen, a Portugal-based cultivator, manufacturer and distributor with a prized EU GMP certified indoor grow facility; CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK; and Bophelo Bioscience & Wellness, a GACP qualified cultivation campus in the Kingdom of Lesotho in Southern Africa. The Company’s seed-to-patient supply chain also includes partnerships with California-based Cookies, a leading globally recognized cannabis company; Cansativa Group, a leading importer and distributor of medical cannabis in Europe; and Cellen Life Sciences’ Leva Clinic, one of the first fully digital pain clinics in the UK.

 

Investor Contact
ir@akandacorp.com

 

Media Contact
Imogen Saunders
Irvine Partners
imogen@irvinepartners.co.uk

 

 

 

GRAPHIC 3 tm2317215d1_ex99-1img01.jpg GRAPHIC begin 644 tm2317215d1_ex99-1img01.jpg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end